Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Finerenone (BAY 94–8862) is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. This observational trial compared the pharmacokinetics of a single oral dose of finerenone 10 mg (immediate‐release tablet) in adults with mild (creatinine clearance [CL CR] 50–80 mL/min; n = 8), moderate (CL CR 30 to < 50 mL/min; n = 8), or severe (CL CR < 30 mL/min; n = 9) renal impairment with those in adults with normal renal function (CL CR > 80 mL/min; n = 8) over 96 hours postdose. Exposure to finerenone was not affected by mild renal impairment. In participants with moderate or severe renal impairment, exposure to finerenone was increased compared with those with normal renal function (increase in area under the curve for unbound finerenone, 57.1% [outlier excluded] and 46.5%, respectively), with moderate to high interindividual variability. Renal impairment had no consistent effect on the maximum plasma concentration, C max (differences in C max for unbound finerenone of +12% and –7% with moderate [outlier excluded] and severe impairment vs normal renal function, respectively). Renal elimination of finerenone is minimal. However, changes in exposure may occur because of the effects of renal impairment on nonrenal routes of elimination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationKolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430 · cited 3×
“20 accumulate at much higher concentrations in the kidney compared with heart tissue.(11) The reduced accumulation in the kidneys, together with minimal renal clearance, suggests a more favourable safety profile of finerenone compared with the other MRAs in patients with renal impairment.”
Background
Cited by
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070942 · Cited by 262
“It is important to highlight that these properties contrast with the long half-life and multiple active metabolites of spironolactone, as well as the fact that spironolactone has a kidney versus heart tissue distribution of approximately 6:1 (approximately 1:1 for finerenone) in rodent models, and that spironolactone…”
BackgroundKolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Vaduganathan, M., Filippatos, G., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A., Brinker, M., Kolkhof, P., Schloemer, P., Lay-Flurrie, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03264-4 · Cited by 158
Lerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
Metadata
- Authors
- Heinig, R., Kimmeskamp‐Kirschbaum, N., Halabi, A., & Lentini, S.
- Venue
- Clinical Pharmacology in Drug Development
- Publisher
- Wiley
- Published
- 2016-07-18
- Volume
- 5
- Issue
- 6
- Pages
- 488-501
- ISSN
- 2160-763X (ISSN-L)
- 2160-7648
- OpenAlex
- W2324541858
- Cited by
- 70
- References
- 4
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment. https://app.cochat.ai/papers/10.1002/cpdd.263
- The paper
- Heinig, R., Kimmeskamp‐Kirschbaum, N., Halabi, A., & Lentini, S. (2016). Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.